A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Patients With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma
Latest Information Update: 23 Feb 2024
At a glance
- Drugs Atezolizumab (Primary) ; Tiragolumab (Primary) ; Cisplatin; Paclitaxel
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms SKYSCRAPER-08
- Sponsors Roche
- 20 Jan 2024 Primary endpoint (Independent Review Facility (IRF)-Assessed Progression-Free Survival (PFS)) has been met, according to Results presented at the 2024 Gastrointestinal Cancers Symposium.
- 20 Jan 2024 Primary endpoint (Overall Survival (OS)) has been met, according to Results presented at the 2024 Gastrointestinal Cancers Symposium.
- 20 Jan 2024 Results presented at the 2024 Gastrointestinal Cancers Symposium